立方制药
(003020)
| 流通市值：45.61亿 | | | 总市值：62.99亿 |
| 流通股本：1.38亿 | | | 总股本：1.90亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 732,436,475.72 | 360,228,684.63 | 1,518,486,284.88 | 1,125,115,398.63 |
| 营业收入 | 732,436,475.72 | 360,228,684.63 | 1,518,486,284.88 | 1,125,115,398.63 |
| 二、营业总成本 | 660,113,516.51 | 323,750,061.35 | 1,355,969,823.26 | 1,000,958,904.88 |
| 营业成本 | 261,868,123.79 | 132,780,939.26 | 468,292,955.43 | 338,419,569.21 |
| 税金及附加 | 10,692,570.65 | 5,499,556.44 | 22,430,949.51 | 16,659,556.84 |
| 销售费用 | 302,485,804.76 | 150,759,043.92 | 692,126,985.3 | 528,538,993.22 |
| 管理费用 | 33,296,782.7 | 15,855,970.08 | 81,563,607.72 | 63,906,891.95 |
| 研发费用 | 51,710,952.03 | 19,080,113.3 | 91,781,591.56 | 53,806,835.68 |
| 财务费用 | 59,282.58 | -225,561.65 | -226,266.26 | -372,942.02 |
| 其中:利息费用 | 1,401,358.42 | 264,361.24 | 1,920,467.98 | 926,622.88 |
| 其中:利息收入 | 1,415,558.37 | 577,334.8 | 2,221,970.61 | 1,666,307.9 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 141,882.36 | -36,243.54 | 1,601,131.58 | 1,247,272.11 |
| 加:投资收益 | 26,123,630.38 | 3,190,997.81 | 11,401,826.54 | 9,025,245.56 |
| 资产处置收益 | 1,769.91 | - | 20,097.78 | 92,974.46 |
| 资产减值损失(新) | -7,889,083.17 | -2,648,176.76 | -12,128,217.98 | -9,054,141.15 |
| 信用减值损失(新) | -1,606,221.27 | -1,396,774.71 | -3,744,159.94 | -1,971,133.3 |
| 其他收益 | 11,929,096.23 | 8,520,164.01 | 18,067,529.39 | 8,066,987.99 |
| 四、营业利润 | 101,024,033.65 | 44,108,590.09 | 177,734,668.99 | 131,563,699.42 |
| 加:营业外收入 | 111,343.53 | 153,684.16 | 1,094,614.85 | 456,195.12 |
| 减:营业外支出 | 255,276.28 | 94,738.69 | 7,013,311.87 | 699,739.71 |
| 五、利润总额 | 100,880,100.9 | 44,167,535.56 | 171,815,971.97 | 131,320,154.83 |
| 减:所得税费用 | 9,349,840.81 | 4,891,955.83 | 19,335,158.35 | 15,663,621.35 |
| 六、净利润 | 91,530,260.09 | 39,275,579.73 | 152,480,813.62 | 115,656,533.48 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 91,530,260.09 | 39,275,579.73 | 152,480,813.62 | 115,656,533.48 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 90,227,143 | 38,250,279.27 | 160,597,316.84 | 118,979,752.45 |
| 少数股东损益 | 1,303,117.09 | 1,025,300.46 | -8,116,503.22 | -3,323,218.97 |
| 扣除非经常损益后的净利润 | 66,220,905.9 | 31,601,663.93 | 149,845,860.02 | 112,020,795.22 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.47 | 0.2 | 0.84 | 0.63 |
| (二)稀释每股收益 | 0.47 | 0.2 | 0.84 | 0.63 |
| 九、综合收益总额 | 91,530,260.09 | 39,275,579.73 | 152,480,813.62 | 115,656,533.48 |
| 归属于母公司股东的综合收益总额 | 90,227,143 | 38,250,279.27 | 160,597,316.84 | 118,979,752.45 |
| 归属于少数股东的综合收益总额 | 1,303,117.09 | 1,025,300.46 | -8,116,503.22 | -3,323,218.97 |
| 公告日期 | 2025-08-26 | 2025-04-22 | 2025-04-22 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |